CYTLIMIC -cytotoxic T lvmphoctyte Immunotherapy in cancer

CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.

Japanese

News Release

Entering into Collaboration Agreement with Immutep Ltd. for the supply of Eftilagimod Alpha

Immutep Limited (ASX: IMM; NASDAQ: IMMP) and CYTLIMIC Inc. (Cytlimic) have entered into a supply and collaboration agreement for the supply of Immutep’s Eftilagimod Alpha (LAG-3Ig, efti or IMP321) as vaccine adjuvant to Cytlimic’s peptide vaccine CYT001.
read more

Registration of Patent on HSP70 (Heat Shock Protein 70) peptides for cancer immunotherapy in Japan

Patent on HSP70-derived peptide, and method of manufacturing pharmaceutical composition for cancer treatment was registered in Japan. A peptide in the patent is used in CYT001, a peptide vaccine under development in Cytlimic.
read more

Presentation at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

The results of a phase I study of Cytlimic peptide vaccine conducted at Yamaguchi University Graduate School of Medicine will be presented at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting being held November 7-11, 2018, in Washington, D.C.
read more

Company

Name
CYTLIMIC Inc.
Business
・Clinical trial of cancer peptide vaccines
・Nonclinical testing of cancer peptide vaccines
・Developing formulations for investigational use vaccines, stability testing
・Promoting application with pharmaceutical companies
Date established
December 16, 2016
Capital
361.5 million yen
Address
MG Meguro Ekimae Building, 15-19, Kamiosaki 2-Chome, Shinagawa-ku, Tokyo
141-0021, Japan

Board

President and CEO

Shun Doi, Ph.D.

Member of the Board

Hiromichi Kimura

CEO and Partner
Fast Track Initiative, Inc.
Member of the Board

Ken Nakamura

Solution Division General Manager
NEC Capital Solutions Limited
Member of the Board

Osamu Fujikawa

Executive Officer
NEC Corporation
Audit & Supervisory Board Member (KANSAYAKU)

Hideyuki Kumazawa

Corporate Strategy Division
NEC Corporation

Science & Technology

aaa
aaa
aaa
aaa

Partner

Oncovir, Inc.
A pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical immunotherapies for cancer and other diseases. Oncovir Hiltonol (Poly ICLC) is supplied to Cytlimic and used in Cytlimic CYT001 cancer vaccine under collaboration agreement between Oncovir and Cytlimic, to synergistically boost patient immune responses to vaccine antigens together with Immutep Efitilagimod Alpha.
Find out more
Immutep Ltd.
A globally active biotechnology company developing LAG-3 related immunotherapeutic product. Immutep Eftilagimod Alpha (LAG-3Ig, IMP321) is supplied to Cytlimic and used in Cytlimic CYT001 cancer vaccine under collaboration agreement between Immutep and Cytlimic, to synergistically boost patient immune responses to vaccine antigens together with Oncovir Hiltonol.
Find out more

Contact

お名前
御社名
メールアドレス
お問合わせ内容

PAGETOP